TWIST BIOSCIENCE CORP

Twist Bioscience’s insider sales show routine liquidity moves, not a warning—focus on its biotech pipeline, earnings outlook, and market dynamics.

Twist Bioscience’s CEO sells 3,000 shares under a 10b5‑1 plan—routine portfolio rebalancing amid strong growth, not a red flag for investors.

Twist Bioscience CEO’s Rule 10b5‑1 trades reveal a disciplined buy‑low, sell‑high strategy, cutting her stake by 25% while locking in gains amid a 23% weekly rally.

Inside Twist Bioscience’s August insider sales: CEO and senior execs sell near highs, signaling routine rebalancing—watch for short‑term liquidity and market sentiment shifts.

Twist Bioscience’s chief accounting officer sold 1,598 shares in a routine sell‑to‑cover move, showing steady liquidity amid growing insider trading and a bullish stock trend.

Cho Dennis sells Twist Bioscience shares on a pre‑planned Rule 10b5‑1 plan, a routine portfolio move amid a strong insider‑buying backdrop.

Finn Patrick John’s insider trades show disciplined liquidity: he sold 68,728 shares at $115‑$123, bought 23,355 at $68, and kept 235,891 shares—an insight into TWIST Bioscience’s risk‑aligned strategy.

CEO Emily Leproust’s plan‑based buy/sell of 113,318 Twist Bioscience shares shows liquidity strategy, not a shift in outlook.

Chess Robert’s dual trade at Twist Bioscience shows insider confidence: a buy below $12, a sell near $111, keeping long‑term exposure while hedging short‑term gains.

Insightful twist: executives sell shares at $109.75, yet Twist Bioscience’s synthetic DNA pipeline and 318% yearly gain keep investors bullish.